Your session is about to expire
← Back to Search
RBN-2397 for Solid Tumors
Study Summary
This trial is testing a new drug, RBN-2397, which inhibits an enzyme called PARP7. This enzyme is switched on by cancer stresses, and allows cancer cells to hide from the immune system. RBN-2397 has been shown in animal studies to inhibit tumor growth and also shuts down the "don't kill me" signal the tumor is sending to evade the immune system. The primary purpose of this study is to determine the maximum tolerated dose of orally administered RBN-2397 in patients with advanced or metastatic solid tumors.
- Solid Tumors, Adult
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the scale of enrollment for this medical research project?
"To conduct this study, Ribon Therapeutics, Inc. must enlist 130 eligible participants to be split between Washington University in St Louis and SCRI-Denver/HealthOne in Denver."
Is this experiment still recruiting participants?
"Clinicaltrials.gov affirms that this trial began on August 1st 2019, and is currently seeking eligible candidates. Most recently the study was updated on July 5th 2022."
Has RBN-2397 attained regulatory authorization from the Food and Drug Administration?
"Our team at Power assigned a score of 1 to RBN-2397's safety, as this is an early phase clinical trial with limited evidence regarding efficacy and hazard."
How numerous are the venues currently conducting this experiment?
"Clinical trial sites operating for this medical study include Washington University in Saint Louis, SCRI-Denver/HealthOne in Denver, and SCRI-Nashville/Tennessee Oncology in Nashville. In addition to these centres, there are 8 other hubs that have been approved by the research team."
Share this study with friends
Copy Link
Messenger